Zerlasiran (SLN360) sodium is a siRNA targeting apolipoprotein A (ApoA). Zerlasiran sodium targets hepatic ApoA synthesis via RNA interference to degrade encoding mRNA. Zerlasiran sodium can be used for the research of atherosclerotic cardiovascular disease and elevated ApoA levels[1][2].
Molecular Weight:
14155.88 (free acid)
Purity:
95.52
Formula:
C443H556F12N144Na38O277P40S10
Target:
Apolipoprotein,Small Interfering RNA (siRNA)
Application Notes:
MCE Product type: Oligonucleotides
* VAT and and shipping costs not included. Errors and price changes excepted